1. Home
  2. CUE vs TLSA Comparison

CUE vs TLSA Comparison

Compare CUE & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • TLSA
  • Stock Information
  • Founded
  • CUE 2014
  • TLSA 2013
  • Country
  • CUE United States
  • TLSA United Kingdom
  • Employees
  • CUE N/A
  • TLSA N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUE Health Care
  • TLSA Health Care
  • Exchange
  • CUE Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • CUE 91.9M
  • TLSA 87.8M
  • IPO Year
  • CUE 2018
  • TLSA 2000
  • Fundamental
  • Price
  • CUE $1.33
  • TLSA $0.75
  • Analyst Decision
  • CUE Strong Buy
  • TLSA
  • Analyst Count
  • CUE 5
  • TLSA 0
  • Target Price
  • CUE $5.00
  • TLSA N/A
  • AVG Volume (30 Days)
  • CUE 271.8K
  • TLSA 1.1M
  • Earning Date
  • CUE 03-10-2025
  • TLSA 02-18-2025
  • Dividend Yield
  • CUE N/A
  • TLSA N/A
  • EPS Growth
  • CUE N/A
  • TLSA N/A
  • EPS
  • CUE N/A
  • TLSA N/A
  • Revenue
  • CUE $9,532,000.00
  • TLSA N/A
  • Revenue This Year
  • CUE $73.11
  • TLSA N/A
  • Revenue Next Year
  • CUE $11.02
  • TLSA N/A
  • P/E Ratio
  • CUE N/A
  • TLSA N/A
  • Revenue Growth
  • CUE 149.53
  • TLSA N/A
  • 52 Week Low
  • CUE $0.45
  • TLSA $0.41
  • 52 Week High
  • CUE $2.37
  • TLSA $1.74
  • Technical
  • Relative Strength Index (RSI)
  • CUE 50.46
  • TLSA 51.78
  • Support Level
  • CUE $1.22
  • TLSA $0.65
  • Resistance Level
  • CUE $1.50
  • TLSA $0.70
  • Average True Range (ATR)
  • CUE 0.12
  • TLSA 0.05
  • MACD
  • CUE -0.02
  • TLSA 0.01
  • Stochastic Oscillator
  • CUE 43.33
  • TLSA 47.20

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: